incb099318
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 30, 2020 (NCT04272034)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Merkel Cell · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Esophageal Squamous Cell Carcinoma · Phase 1
- Mesothelioma · Phase 1
- Nasopharyngeal Carcinoma · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Penile Neoplasms · Phase 1
- Rectal Neoplasms · Phase 1
- Small Cell Lung Carcinoma · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04272034 | Phase 1 | May 30, 2020 | Incyte |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 1 | 1 | 1 | 2020 |
1 organizations
Page 1 / 1